Akero Therapeutics (NASDAQ: AKRO) Chief Development Officer Yale Catriona sold 1,633 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission.

Akero Therapeutics (NASDAQ: AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504.

Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ: AKRO), sold 6,620 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission ...

Akero Therapeutics (NASDAQ: AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504.

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening ...

Review the current valuation for Akero Therapeutics Inc (AKRO:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

The VC is funded mainly via Rigmora Biotech Investor One and Rigmora Biotech Investor Two, according to a June 27 press release. Both funds are part of Rigmora Holdings, a family office that manages ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

Review Akero Therapeutics Inc (AKRO:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” takeover potential. Jefferies thinks big pharma companies are "still ...

Get the detailed quarterly/annual income statement for Akero Therapeutics, Inc. (AKRO). Find out the revenue, expenses and profit or loss over the last fiscal year.